Quadramet
Quadramet (Samarium Sm-153) is a radiopharmaceutical agent used for palliative treatment of bone pain in patients with confirmed osteoblastic (bone-forming) metastatic lesions, particularly from prostate and breast cancers. It delivers targeted radiation directly to bone metastases to provide pain relief when standard analgesics are inadequate.
A radiopharmaceutical that targets bone metastases with radiation to provide palliative pain relief in cancer patients.
Key facts at a glance
- RxNorm
- 203876
- Generic
- Quadramet
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Quadramet is indicated for the relief of bone pain in patients with confirmed osteoblastic metastatic bone lesions, most commonly from prostate cancer and breast cancer. It is used when pain is inadequately controlled with conventional analgesics such as NSAIDs or opioids.
Quadramet contains samarium-153 bound to EDTMP (ethylenediaminetetramethylenephosphonic acid), a bone-seeking molecule. After intravenous administration, it localizes preferentially to areas of increased bone turnover, such as metastatic lesions. The radioactive samarium-153 emits beta radiation that targets nearby tumor cells and nerve endings in the bone, reducing pain signals.
Quadramet is administered as a single intravenous injection, typically by a nuclear medicine specialist. Pain relief usually begins within 1-2 weeks and can last several weeks to months. Patients should be monitored for myelosuppression (low blood counts), and standard radiation safety precautions are required. It is not intended for curative treatment and is used solely for palliative symptom management.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 29, 2026. · Read our editorial policy